Kelly S. DeMartini, PhD
Cards
Appointments
Titles
Administrative Director, Center for the Translational Neuroscience of Alcoholism
Contact Info
Psychological Medicine Section
Psychiatry, 20 York St., Fitkin Building
New Haven, CT 06510
United States
Appointments
Titles
Administrative Director, Center for the Translational Neuroscience of Alcoholism
Contact Info
Psychological Medicine Section
Psychiatry, 20 York St., Fitkin Building
New Haven, CT 06510
United States
Appointments
Titles
Administrative Director, Center for the Translational Neuroscience of Alcoholism
Contact Info
Psychological Medicine Section
Psychiatry, 20 York St., Fitkin Building
New Haven, CT 06510
United States
About
Titles
Research Scientist of Psychiatry
Administrative Director, Center for the Translational Neuroscience of AlcoholismBiography
I am an expert in the development and analysis of alcohol interventions and the application of state-of-the-art statistical models to understand heavy drinking and predictors of hazardous alcohol use. My research focuses on the development and utilization of technology-based substance use and lifestyle health interventions. A key goal of my work is to utilize wearable and smartphone technologies for clinical digital phenotyping. This objective, data-driven measurement of individual health and functioning via personal biosensors can help build understanding of the connections among substance use and other health behaviors, including sleep, cardiac and respiratory functioning, and physical activity. I am particularly interested in how the use of these technologies can increase access to health interventions and engagement with health interventions across patient populations.
Appointments
Psychiatry
Research ScientistPrimary
Other Departments & Organizations
- ADVANCE Study
- Call it a Night
- Center for the Translational Neuroscience of Alcohol
- DIGITAL Insights Lab
- Division of Addictions
- Psychiatry
- Psychology Section
- Yale Medicine
Education & Training
- Postdoctoral Fellow
- Yale School of Medicine (2013)
- PhD
- Syracuse University (2011)
- Predoctoral Fellow
- Yale School of Medicine (2011)
- MS
- Syracuse University (2007)
- BA
- Boston College (2004)
Research
Overview
My research is broadly aimed at the development of treatments and interventions for alcohol use across patient populations, including young adult drinkers and patients with alcohol use disorders and medical comorbidities. Epidemiological data indicate that rates of heavy drinking in young adults have not decreased, despite decades of intensive research to develop efficacious interventions for this population. Among all those over 18 years of age in the United States, approximately 25% report binge drinking in the past month. Across populations, heavy alcohol consumption is associated with a host of negative consequences, including legal, medical, relational and other problems, even alcohol-related death. A great deal more research is needed to develop novel alcohol use interventions and to identify mechanisms to maximize the benefit of current treatments.
My research focuses on:
1. The development of mobile technology-based interventions, including SMS-based, smartphone, and wearable platforms
2. Quantitative modeling (including person-centered models and Baysian models) of factors related to trajectories of alcohol use both during and post-treatment
3. Understanding factors, including gender, that mediate or moderate alcohol treatment response
4. The development of brief alcohol interventions for young adult drinkers
I have a particular interest in the development of technology-based treatments for hazardous drinking and alcohol use disorders, especially for patients with comorbid medical conditions. These conditions can limit a patient's ability to travel for treatment; provide adjunct care via technology-based interventions can provide necessary, additional support. For young adults, technology-based treatments can increase their willingness to participate in treatment and match their preferences for how to engage providers.
Overall, my research aims to develop efficacious treatments for alcohol use disorders, particularly treatments that can be accessed outside of the typical treatment setting. Building these treatments requires thorough understanding of key treatment mediators and moderators, including those that vary over time. Treatments that increase access to care and account for these person-specific mediators could greatly increase efficacy.
Medical Subject Headings (MeSH)
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Lisa Fucito, PhD
John Krystal, MD
Nancy Schmieder Redeker, RN, MSN, PhD, FAHA, FAAN
Angela Haeny, PhD
Garrett Ash, PhD
Dwain Fehon, PsyD
Publications
Featured Publications
Dynamic structural equation modeling of the relationship between alcohol habit and drinking variability
DeMartini KS, Gueorguieva R, Taylor JR, Krishnan-Sarin S, Pearlson G, Krystal JH, O'Malley SS. Dynamic structural equation modeling of the relationship between alcohol habit and drinking variability. Drug And Alcohol Dependence 2021, 233: 109202. PMID: 35151022, PMCID: PMC10046111, DOI: 10.1016/j.drugalcdep.2021.109202.Peer-Reviewed Original ResearchCitationsMapping data‐driven individualized neurobehavioral phenotypes in heavy alcohol drinkers
DeMartini KS, Gueorguieva R, Pearlson G, Krishnan‐Sarin S, Anticevic A, Ji LJ, Krystal JH, O’Malley S. Mapping data‐driven individualized neurobehavioral phenotypes in heavy alcohol drinkers. Alcohol Clinical And Experimental Research 2021, 45: 841-853. PMID: 33605439, DOI: 10.1111/acer.14580.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsConfirmatory factor analysisIncentive salienceNeurofunctional domainsAlcohol use disorderExecutive functionLatent factorsPhysical neglectSelf-report measuresChildhood emotional abuseUse disordersChildhood physical neglectEarly life stressSignificant predictorsMultiple significant predictorsMultiple causes modelCurrent AUDNegative emotionalityAddiction developmentEmotional abuseChildhood neglectFactor structureDrinking frequencySalienceCause modelFactor analysisThe Impact of Integrated Behavioral Healthcare on Glycemic Control
MacGregor KL, DeMartini KS, Barry-Menkhaus SA, Derr AG, Thompson MJ. The Impact of Integrated Behavioral Healthcare on Glycemic Control. Journal Of Clinical Psychology In Medical Settings 2021, 29: 636-644. PMID: 34436717, DOI: 10.1007/s10880-021-09817-w.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsGlycemic controlMetabolic statusBehavioral health encountersPost-intervention slopeStandard of carePatient's metabolic statusBehavioral healthcareDiabetes outcomesHealth encountersPsychosocial factorsBehavioral healthSignificant linear decreaseVisitsAdultsMixed effectsSlope trajectoriesHbA1cHealthcareClinicCareA Multimodal Mobile Sleep Intervention for Young Adults Engaged in Risky Drinking: Protocol for a Randomized Controlled Trial (Preprint)
Fucito LM, Ash GI, DeMartini KS, Pittman B, Barnett NP, Li CR, Redeker NS, O'Malley SS. A Multimodal Mobile Sleep Intervention for Young Adults Engaged in Risky Drinking: Protocol for a Randomized Controlled Trial (Preprint). JMIR Research Protocols 2021, 10: e26557. PMID: 33635276, PMCID: PMC7954653, DOI: 10.2196/26557.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSleep hygiene adviceINTERNATIONAL REGISTERED REPORT IDENTIFIERHeavy-drinking young adultsHygiene adviceSleep interventionsYoung adultsAlcohol diaryAlcohol use disorder riskRisky alcohol consumptionAlcohol use disorderLow-cost interventionAlcohol behavior changeControlled TrialsWeb-based sessionsBrief adviceHealth coachesRisk factorsPoor sleepRecent heavy drinkingSleep characteristicsUse disordersAlcohol consumptionAlcohol-related consequencesPriority populationsSecondary aimText Messaging to Reduce Alcohol Relapse in Prelisting Liver Transplant Candidates: A Pilot Feasibility Study
DeMartini KS, Schilsky ML, Palmer A, Fehon DC, Zimbrean P, O'Malley SS, Lee HB, Toll BA. Text Messaging to Reduce Alcohol Relapse in Prelisting Liver Transplant Candidates: A Pilot Feasibility Study. Alcohol Clinical And Experimental Research 2018, 42: 761-769. PMID: 29498753, PMCID: PMC6438371, DOI: 10.1111/acer.13603.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAlcoholic liver diseaseLiver transplant candidatesLiver transplant patientsStandard careEfficacy outcomesTransplant patientsTransplant candidatesFeasibility outcomesTM participantsAlcohol interventionsClinical efficacy outcomesLiver transplantation programPreliminary efficacy outcomesPrimary feasibility outcomePilot feasibility trialPilot feasibility studyRelapse prevention interventionsBetter treatment outcomesLiver diseaseFeasibility trialUnited NetworkTransplantation programIntervention satisfactionTreatment outcomesAlcohol relapseSensitivity, specificity, and tolerability of the BACTrack Skyn compared to other alcohol monitoring approaches among young adults in a field‐based setting
Ash GI, Gueorguieva R, Barnett NP, Wang W, Robledo DS, DeMartini KS, Pittman B, Redeker NS, O’Malley S, Fucito LM. Sensitivity, specificity, and tolerability of the BACTrack Skyn compared to other alcohol monitoring approaches among young adults in a field‐based setting. Alcohol Clinical And Experimental Research 2022, 46: 783-796. PMID: 35567595, PMCID: PMC9179100, DOI: 10.1111/acer.14804.Peer-Reviewed Original ResearchCitationsAltmetricDrinking Goals and Attainment in a Naltrexone Trial of Young Adult Heavy Drinkers
DeMartini KS, Foster DW, Corbin WR, Fucito LM, Romano D, Leeman RF, Kranzler HR, O’Malley S. Drinking Goals and Attainment in a Naltrexone Trial of Young Adult Heavy Drinkers. Journal Of Consulting And Clinical Psychology 2018, 86: 765-774. PMID: 30138015, PMCID: PMC6435339, DOI: 10.1037/ccp0000323.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsTreatment outcomesAdult heavy drinkersYoung adult heavy drinkersHeavy drinkersDrinking goalEnd of treatmentPeak drinkingBetter treatment outcomesAlcohol use disorderImpact treatment outcomesTypical drinkingYoung adult drinkersEfficacy trialsUse disordersBrief counselingGoal settingIntervention effectsGoal-setting exercisesAdult drinkersDrinkersOutcomesDrinkingTreatmentImportant targetMidtreatment
2024
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement
Lee B, Witkiewitz K, Mellinger J, Anania F, Bataller R, Cotter T, Curtis B, Dasarathy S, DeMartini K, Diamond I, Diazgranados N, DiMartini A, Falk D, Fernandez A, German M, Kamath P, Kidwell K, Leggio L, Litten R, Louvet A, Lucey M, McCaul M, Sanyal A, Singal A, Sussman N, Terrault N, Thursz M, Verna E, Radaeva S, Nagy L, Mitchell M. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement. Nature Reviews Gastroenterology & Hepatology 2024, 1-20. PMID: 38849555, DOI: 10.1038/s41575-024-00936-x.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAlcohol-associated liver diseaseAlcohol use disorderLiver diseaseClinical trialsRisk of decompensation of liver diseaseAlcohol useUse disorderTreatment of alcohol use disordersExpert panel consensus statementDecompensation of liver diseaseAddiction medicine specialistsProgression of liver diseaseLiver-related outcomesNational Institute of Alcohol AbuseDesigning clinical trialsEffects of alcohol useConsensus of expert opinionTask ForceConsensus statementMedicine specialistsAlcohol abuseHeavy drinkingDiseaseClinical trialistsPatients
2022
Within‐ and between‐person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation
Waddell JT, Corbin WR, MacKinnon DP, Leeman RF, DeMartini KS, Fucito LM, Kranzler HR, O’Malley S. Within‐ and between‐person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation. Alcohol Clinical And Experimental Research 2022, 46: 477-491. PMID: 35076087, PMCID: PMC9679805, DOI: 10.1111/acer.14780.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMedication dosageYoung adultsLight drinkingSubjective responsesSubjective effectsHeavy drinkingPlacebo-controlled studyEffect sizePerson effectsEffective treatmentNaltrexoneDrinking daysNaltrexone efficacySmall effect sizesDrinking levelsCravingDrinkingAdultsLaboratory-based studiesPillsMomentary assessmentEfficacyTreatment conditionsDrinking environmentsDaily diary data
2021
Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder. A pilot randomised trial
Patel KT, Stevens MC, Dunlap A, Gallagher A, O’Malley S, DeMartini K, Potenza MN, Krystal JH, Pearlson GD. Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder. A pilot randomised trial. Neuropsychopharmacology 2021, 47: 840-846. PMID: 34475522, PMCID: PMC8882177, DOI: 10.1038/s41386-021-01157-5.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsProtein tyrosine kinasesSrc regulationSrc familyProtein kinaseTyrosine kinaseFyn kinaseSrc inhibitorSrc/FynDependent pathwayKinaseNMDAR upregulationNMDAR functionNMDA receptorsRegulationSaracatinibGluN2B subunitGlutamate receptorsFynInhibitorsReceptorsSubunitsN-methyl-D-aspartate (NMDA) glutamate receptorsPrevious evidence
Clinical Care
Overview
Clinical Specialties
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- April 10, 2023
Fucito, DeMartini Awarded Grant by NIAAA
- May 18, 2022
Yale Researchers Compare BACTrack Skyn to Other Alcohol Monitoring Approaches
- November 30, 2017
Yale study: Young adults could be at risk of heavier drinking with shortened night of sleep
- February 25, 2015
Young problem drinkers consume less if they take naltrexone
Related Links
Get In Touch
Contacts
Psychological Medicine Section
Psychiatry, 20 York St., Fitkin Building
New Haven, CT 06510
United States